An imidazoline receptor agonist, moxonidine, in optimization of arterial hypertension treatment among postmenopausal women
Abstract
Aim. To study efficacy and tolerability of moxonidine and its combination with hormone replacement therapy, HRT (17-β-estradiol and dehydrogesterone), in postmenopausal women with essential arterial hypertension (EAH). Material and methods. The study included 68 women with Stage I-II EAH and climacteric syndrome (CS). Participants randomly received moxonidine (Group I), or its combination with HRT (Group II). Blood pressure (BP) was measured by Korotkoff method. Echocardiography, lipid profile and hemostasis assessment were performed. Quality of life was assessed by modified menopausal index. Results. Good self-reported tolerability of the treatment and menopausal index decrease were observed in both groups. In Group I, systolic and diastolic BP levels significantly decreased by Month 3, and CS symptom severity reduced by Month 6. At the same time, moxonidine and HRT combination substantially decreased disturbed lipid profile and hemostasis parameter levels, comparing to moxonidine monotherapy. Conclusion. Moxonidine is effective in treating EAH in postmenopausal women. HRT enhanced antihypertensive moxonidine effects, as well as improvements in lipid metabolism and hemostasis.
About the Authors
A. B. Bakhshaliev
Dzh. Abdullaev Cardiology Research Institute. Baku
Azerbaijan
Azerbaijan
G. M. Sabzalieva
Dzh. Abdullaev Cardiology Research Institute. Baku
Azerbaijan
Azerbaijan
T. Sh. Dzhakhangirov
Dzh. Abdullaev Cardiology Research Institute. Baku
Azerbaijan
Azerbaijan
References
1. Сметник В.П. Защитное влияние эстрогенов на сердечнососудистую систему. Cons med (экстравыпуск) 2002; 3-6.
2. Ernsberger P, Haxhiu MA, Graff LM. A novel mechanism of action for hypertension control: moxonidine as a selective 1,-imidazoline agonist «Cardiovascular drugs and therapy». Boston 1994; 27-41.
3. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med Hypotheses 1995; 44: 217-25.
4. Колб В.Г, Камышников В.С. Справочник по клинической химии, Минск «Беларусь» 1982; 366 с.
5. Андреенко Г.В., Карабасова Н.Н. Методы исследования фибринолитической системы крови. Москва 1981; 125 c.
6. Козловская Л.В., Николаев А.Ю. Учебное пособие по клиническим лабораторным методом исследования. Москва «Медицина» 1985; 85 c.
7. Лифщиц В.И., Сидельникова В.И. Медицинские лабораторные анализы. Справочник. Москва «Триада-X» 2000; 113 с.
8. Мильто А.С., Толкачева В.В., Кобалава Ж.Д. Моксонидин в комбинированной терапии гипертонической болезни с высоким риском с сердечно-сосудистых осложнений. Клин фарм тер 2001; 10(4): 68-71.
9. Ольбинская Л.И., Боченков Ю.В. Опыт применения агониста имидазолиновых рецепторов моксонидина (цинта) при долгосрочной терапии артериальной гипертонии у больных сахарным диабетом II типа. Клин фарм тер 2000; 9(3): 58-60.
10. Prichard BN, Graham BR. I r-imidazoline Agonists.General Clinical Pharmacology of Imidazoline receptors. Implications for trhe treatment in the elderly. Drugs 2000; 17(2): 133-59.
11. Benedict CR. Centrally Acting Antihypertensive Drugs: Reemergence of Sympathetic Inhibition in the Treatment of hypertension. Curr Hypertens Rep 1999; 4: 305-12.
12. Schliker E. Central presynaptic alpha-2-autoreceptors are involved in the blood pressure- lowering effects of moxonidine. J Сardiovasc Pharmacol 1990; 16: 15-22.
13. Miitrovic V, Patyna W. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991; 5: 967-72.
14. Kannel WB. Epidemiological implications of left ventricular hypertrophy. Un: Cruickshank J.M., Messerli F.H., eds. Left ventricular hypertrophy and its regression. London: Science Press 1992; 359: 1-13.
15. Levy D, Savage D, Garrison K, et al. Echocardiographic criterior for the left ventricular hypertrophy: the Fremingham heart study. Am J Cardiol 1987; 59: 956-60.
16. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17(Suppl. 3): S29-35.
17. Velliquette RA, Ernsberger P. Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 2003; 307: 1104-11.
18. Pedersen SB, Bak JF, Holck P, et al. Epinefrine stimulates human muscle lipoprotein lipase activity in vivo. Metabolism 1999; 48: 461-4.
19. Kirch W, Hult HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30: 1088-95.
20. Mancia G, Grassi G, Giannattasio C, Seravalle G. Symphateric activation in the pathogenesis of progression of organ damage. Hypertension 1999; 34(pt 2):724-8.
21. Ольбинская Л.И., Боченков Ю.В. Опыт применения агониста имидазолиновых рецепторов моксонидина (цинта) при долгосрочной терапии артериальной гипертонии у больных сахарным диабетом II типа. Клин фарм тер 2000; 9(3): 58-60.
22. Elisaf MS, Petris C, Bairaktari E, et al. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Hum Hypertens 1999; 13(11): 781-5.
23. Аничков Д.А., Шостак Н.А. Благоприятное влияние моксонидина на показатели липидного обмена у больных с метаболическим синдромом. Кардиология 2004; 9: 13-5.
24. Подзолков В.И., Брагина А.Е., Маколкин В.И. Патогенетическая роль мокмонидина при лечении артериальной гипертензии у женщин в перименопаузе. Кардиология 2002; 11: 32-5.
25. Lumb PJ, Mcmahon Z, ChikG, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patient with hypertension. International J Clin Pract 2004; 58(Suppl 5): 465-8.
26. Аничков Д.А., Шостак Н.А. Эффективность моксонидина у женщин с артериальной гипертензией в рамках метаболического синдрома при исходно высокой частоте сердечных сокращений. Кардиология 2002; 11: 40-3.
27. Mercuro G, Zoncu S, Saiu F, et al. Menopause induce by oophorectomy reveales a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 2004; 47: 131-8.
28. Affinito P, Palomba S, Bonifacio M, et al. Effects of hormonal replacement therapy in postmenopausal hypertensive patients. Maturitas 2001; 40: 75-83.
29. Haywards C, Samaras K, Campbell L, Kelly R. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 2002; 14(7): 699-703.
30. Lip G, Beevers M, Churchill D, Beevers D. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994; 8(7): 491-4.
31. Szekacs B, Vajo Z, Acs N, et al. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000; 7: 31-5.
32. Van Ittersum F, van Baal W, Kenemans P, et al. Ambulatory – not office – blood pressure decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998; 11(10): 1147-52.
33. Vestergaard P, Hermann A, Stilgren L, et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure – a randomized controlled study. Maturitas 2003; 46: 123-32.
34. Butkevich A, Abraham C, Phillips R. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women. Am J Hypertens 2000; 13(9): 1039-41.
35. Genazzani A, Gambacciani M. Hormone replacement therapy: the perspectives for the 21st century. Maturitas 1999; 32: 11-7.
36. Baker L, Meldrum K, Wang M, et al. The role of estrogen in cardiovascular disease. J Surg Res 2003; 115: 325-44.
37. Morales D, McGowan K, Grant D, et al. Circulation 1995; 91: 755-63.
38. Spyridopoulos I, Sullivan A, Kearney M, et al. Estrogen-receptormediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation 1997; 95: 1505-14.
39. Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection of no effect? Maturitas 2001; 38: 243-61.
40. Landau R, Poulos J. The metabolic influence of progestins. AdVol Metab Disord 1971; 5: 119-47.
41. Sealey J, Itskovitz-Eldor J, Rubattu S, et al. Estradiol and progesterone related increases in rennin-aldosterone system during ovarian stimulation and early pregnancy. J Clin Endocr Metab 1994; 79: 258-64.
42. Караченцов А.Н., Сергеев В.П. Вазоактивные эффекты половых гормонов. Пробл эндокр 1997; 41(2): 45-53.
43. Barbagallo M, Shan J, Pang P, Resnik L. Vascular effects of progesterone: role of intracellular calcium metabolism. Am J Hypertens 1995; 8: 66A.
Review
For citations:
Bakhshaliev A.B., Sabzalieva G.M., Dzhakhangirov T.Sh. An imidazoline receptor agonist, moxonidine, in optimization of arterial hypertension treatment among postmenopausal women. Cardiovascular Therapy and Prevention. 2006;5(1):37-44. (In Russ.)
Views:
528
Email this article 
